Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

Core Outcome Measures in Preclinical Assessment of Candidate Analgesics.

Negus SS.

Pharmacol Rev. 2019 Apr;71(2):225-266. doi: 10.1124/pr.118.017210. Review.

2.

Role of agonist efficacy in exposure-induced enhancement of mu opioid reward in rats.

Moerke MJ, Negus SS.

Neuropharmacology. 2019 Jun;151:180-188. doi: 10.1016/j.neuropharm.2019.03.020. Epub 2019 Mar 14.

PMID:
30880123
3.

Sex differences in opioid reinforcement under a fentanyl vs. food choice procedure in rats.

Townsend EA, Negus SS, Caine SB, Thomsen M, Banks ML.

Neuropsychopharmacology. 2019 Feb 28. doi: 10.1038/s41386-019-0356-1. [Epub ahead of print]

PMID:
30818323
4.

Testing the 10 most wanted: a preclinical algorithm to screen candidate opioid use disorder medications.

Banks ML, Townsend EA, Negus SS.

Neuropsychopharmacology. 2019 May;44(6):1011-1012. doi: 10.1038/s41386-019-0336-5. Epub 2019 Feb 9. Review. No abstract available.

PMID:
30739125
5.

Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.

Schwienteck KL, Faunce KE, Rice KC, Obeng S, Zhang Y, Blough BE, Grim TW, Negus SS, Banks ML.

Neuropharmacology. 2019 May 15;150:200-209. doi: 10.1016/j.neuropharm.2019.01.020. Epub 2019 Jan 18.

PMID:
30660628
6.

Effects of the α2/α3-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: comparison with ketorolac and diazepam.

Moerke MJ, Li G, Golani LK, Cook J, Negus SS.

Behav Pharmacol. 2019 Jan 10. doi: 10.1097/FBP.0000000000000464. [Epub ahead of print]

PMID:
30640180
7.

Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.

Sakloth F, Leggett E, Moerke MJ, Townsend EA, Banks ML, Negus SS.

Exp Clin Psychopharmacol. 2019 Jun;27(3):215-226. doi: 10.1037/pha0000253. Epub 2019 Jan 10.

PMID:
30628811
8.

Determinants of opioid abuse potential: Insights using intracranial self-stimulation.

Negus SS, Moerke MJ.

Peptides. 2019 Feb;112:23-31. doi: 10.1016/j.peptides.2018.10.007. Epub 2018 Nov 1. Review.

PMID:
30391425
9.

Abuse Potential of Biased Mu Opioid Receptor Agonists.

Negus SS, Freeman KB.

Trends Pharmacol Sci. 2018 Nov;39(11):916-919. doi: 10.1016/j.tips.2018.08.007. Review.

PMID:
30343727
10.

Effects of repeated treatment with methcathinone, mephedrone, and fenfluramine on intracranial self-stimulation in rats.

Suyama JA, Banks ML, Negus SS.

Psychopharmacology (Berl). 2018 Sep 19. doi: 10.1007/s00213-018-5029-y. [Epub ahead of print]

PMID:
30232529
11.

Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys.

Schwienteck KL, Negus SS, Banks ML.

Behav Pharmacol. 2019 Jun;30(4):358-362. doi: 10.1097/FBP.0000000000000437.

PMID:
30212383
12.

Interactions between Cocaine and the Putative Allosteric Dopamine Transporter Ligand SRI-31142.

Moerke MJ, Ananthan S, Banks ML, Eltit JM, Freitas KC, Johnson AR, Saini SK, Steele TWE, Negus SS.

J Pharmacol Exp Ther. 2018 Nov;367(2):222-233. doi: 10.1124/jpet.118.250902. Epub 2018 Aug 27.

PMID:
30150482
13.

Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats.

Johnson AR, Banks ML, Selley DE, Negus SS.

Neuropsychopharmacology. 2018 Jul;43(8):1753-1762. doi: 10.1038/s41386-018-0071-3. Epub 2018 Apr 19.

PMID:
29703999
14.

Effects of N-Alkyl-4-Methylamphetamine Optical Isomers on Plasma Membrane Monoamine Transporters and Abuse-Related Behavior.

Battisti UM, Sitta R, Harris A, Sakloth F, Walther D, Ruchala I, Negus SS, Baumann MH, Glennon RA, Eltit JM.

ACS Chem Neurosci. 2018 Jul 18;9(7):1829-1839. doi: 10.1021/acschemneuro.8b00138. Epub 2018 May 14.

15.

Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats.

Sakloth F, Negus SS.

Exp Clin Psychopharmacol. 2018 Apr;26(2):195-204. doi: 10.1037/pha0000183. Epub 2018 Mar 12.

16.

Addressing the Opioid Crisis: The Importance of Choosing Translational Endpoints in Analgesic Drug Discovery.

Negus SS.

Trends Pharmacol Sci. 2018 Apr;39(4):327-330. doi: 10.1016/j.tips.2018.02.002. Epub 2018 Feb 28. Review.

17.

Lack of paclitaxel effects on intracranial self-stimulation in male and female rats: comparison to mechanical sensitivity.

Legakis LP, Bigbee JW, Negus SS.

Behav Pharmacol. 2018 Apr;29(2 and 3-Spec Issue):290-298. doi: 10.1097/FBP.0000000000000378.

18.

Repeated Morphine Produces Sensitization to Reward and Tolerance to Antiallodynia in Male and Female Rats with Chemotherapy-Induced Neuropathy.

Legakis LP, Negus SS.

J Pharmacol Exp Ther. 2018 Apr;365(1):9-19. doi: 10.1124/jpet.117.246215. Epub 2018 Jan 23.

19.

Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys.

Cornelissen JC, Obeng S, Rice KC, Zhang Y, Negus SS, Banks ML.

J Pharmacol Exp Ther. 2018 Apr;365(1):37-47. doi: 10.1124/jpet.117.246439. Epub 2018 Jan 12.

20.

Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.

Lazenka ML, Moerke MJ, Townsend EA, Freeman KB, Carroll FI, Negus SS.

Psychopharmacology (Berl). 2018 Jan;235(1):203-213. doi: 10.1007/s00213-017-4758-7. Epub 2017 Oct 24.

21.

Maintenance on naltrexone+amphetamine decreases cocaine-vs.-food choice in male rhesus monkeys.

Moerke MJ, Banks ML, Cheng K, Rice KC, Negus SS.

Drug Alcohol Depend. 2017 Dec 1;181:85-93. doi: 10.1016/j.drugalcdep.2017.09.020. Epub 2017 Oct 13.

22.

Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats.

Townsend EA, Naylor JE, Negus SS, Edwards SR, Qureshi HN, McLendon HW, McCurdy CR, Kapanda CN, do Carmo JM, da Silva FS, Hall JE, Sufka KJ, Freeman KB.

Psychopharmacology (Berl). 2017 Sep;234(17):2597-2605. doi: 10.1007/s00213-017-4652-3. Epub 2017 May 31.

23.

Utility of Nonhuman Primates in Substance Use Disorders Research.

Banks ML, Czoty PW, Negus SS.

ILAR J. 2017 Dec 1;58(2):202-215. doi: 10.1093/ilar/ilx014. Review.

24.

N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability.

Solis E Jr, Partilla JS, Sakloth F, Ruchala I, Schwienteck KL, De Felice LJ, Eltit JM, Glennon RA, Negus SS, Baumann MH.

Neuropsychopharmacology. 2017 Sep;42(10):1950-1961. doi: 10.1038/npp.2017.98. Epub 2017 May 22.

25.

Effects of Acute and Chronic Treatments with Dopamine D2 and D3 Receptor Ligands on Cocaine versus Food Choice in Rats.

Thomsen M, Barrett AC, Butler P, Negus SS, Caine SB.

J Pharmacol Exp Ther. 2017 Jul;362(1):161-176. doi: 10.1124/jpet.117.241141. Epub 2017 May 4.

26.

Apparent CB1 Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model.

Grim TW, Morales AJ, Thomas BF, Wiley JL, Endres GW, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2017 Jul;362(1):210-218. doi: 10.1124/jpet.117.240192. Epub 2017 Apr 25.

27.
28.

Relief of Pain-Depressed Behavior in Rats by Activation of D1-Like Dopamine Receptors.

Lazenka MF, Freitas KC, Henck S, Negus SS.

J Pharmacol Exp Ther. 2017 Jul;362(1):14-23. doi: 10.1124/jpet.117.240796. Epub 2017 Apr 14.

29.

Role of d-amphetamine and d-methamphetamine as active metabolites of benzphetamine: Evidence from drug discrimination and pharmacokinetic studies in male rhesus monkeys.

Banks ML, Snyder RW, Fennell TR, Negus SS.

Pharmacol Biochem Behav. 2017 May;156:30-38. doi: 10.1016/j.pbb.2017.03.008. Epub 2017 Mar 31.

30.

Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents.

Altarifi AA, David B, Muchhala KH, Blough BE, Akbarali H, Negus SS.

J Psychopharmacol. 2017 Jun;31(6):730-739. doi: 10.1177/0269881116689257. Epub 2017 Feb 1.

31.

Oral modafinil facilitates intracranial self-stimulation in rats: comparison with methylphenidate.

Lazenka MF, Negus SS.

Behav Pharmacol. 2017 Jun;28(4):318-322. doi: 10.1097/FBP.0000000000000288.

32.

Insights from Preclinical Choice Models on Treating Drug Addiction.

Banks ML, Negus SS.

Trends Pharmacol Sci. 2017 Feb;38(2):181-194. doi: 10.1016/j.tips.2016.11.002. Epub 2016 Dec 2. Review.

33.
34.

Effects of 21-day d-amphetamine and risperidone treatment on cocaine vs food choice and extended-access cocaine intake in male rhesus monkeys.

Hutsell BA, Negus SS, Banks ML.

Drug Alcohol Depend. 2016 Nov 1;168:36-44. doi: 10.1016/j.drugalcdep.2016.08.637. Epub 2016 Sep 5.

35.

Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays.

Grim TW, Morales AJ, Gonek MM, Wiley JL, Thomas BF, Endres GW, Sim-Selley LJ, Selley DE, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2016 Nov;359(2):329-339. Epub 2016 Aug 17.

37.

Pharmacokinetic-Pharmacodynamic (PKPD) Analysis with Drug Discrimination.

Negus SS, Banks ML.

Curr Top Behav Neurosci. 2018;39:245-259. doi: 10.1007/7854_2016_36. Review.

38.

Sex differences in abuse-related neurochemical and behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats.

Lazenka MF, Suyama JA, Bauer CT, Banks ML, Negus SS.

Pharmacol Biochem Behav. 2017 Jan;152:52-60. doi: 10.1016/j.pbb.2016.08.004. Epub 2016 Aug 24.

39.

Dissociable effects of the prodrug phendimetrazine and its metabolite phenmetrazine at dopamine transporters.

Solis E Jr, Suyama JA, Lazenka MF, DeFelice LJ, Negus SS, Blough BE, Banks ML.

Sci Rep. 2016 Aug 12;6:31385. doi: 10.1038/srep31385.

40.

Development of a translational model to screen medications for cocaine use disorder II: Choice between intravenous cocaine and money in humans.

Lile JA, Stoops WW, Rush CR, Negus SS, Glaser PE, Hatton KW, Hays LR.

Drug Alcohol Depend. 2016 Aug 1;165:111-9. doi: 10.1016/j.drugalcdep.2016.05.022. Epub 2016 May 28.

41.

Development of a translational model to screen medications for cocaine use disorder I: Choice between cocaine and food in rhesus monkeys.

Johnson AR, Banks ML, Blough BE, Lile JA, Nicholson KL, Negus SS.

Drug Alcohol Depend. 2016 Aug 1;165:103-10. doi: 10.1016/j.drugalcdep.2016.05.021. Epub 2016 May 28.

42.

Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys.

Smith DA, Negus SS, Poklis JL, Blough BE, Banks ML.

Addict Biol. 2017 Sep;22(5):1169-1178. doi: 10.1111/adb.12399. Epub 2016 Apr 6.

43.

Opposing effects of dopamine D1- and D2-like agonists on intracranial self-stimulation in male rats.

Lazenka MF, Legakis LP, Negus SS.

Exp Clin Psychopharmacol. 2016 Jun;24(3):193-205. doi: 10.1037/pha0000067. Epub 2016 Mar 17.

44.
45.

Cocaine-like discriminative stimulus effects of phendimetrazine and phenmetrazine in rats.

Bauer CT, Negus SS, Blough BE, Banks ML.

Behav Pharmacol. 2016 Apr;27(2-3 Spec Issue):192-5. doi: 10.1097/FBP.0000000000000225.

46.

Preclinical Abuse Potential Assessment of Flibanserin: Effects on Intracranial Self-Stimulation in Female and Male Rats.

Lazenka MF, Blough BE, Negus SS.

J Sex Med. 2016 Mar;13(3):338-49. doi: 10.1016/j.jsxm.2015.12.031. Epub 2016 Jan 28.

47.

Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats.

Hutsell BA, Baumann MH, Partilla JS, Banks ML, Vekariya R, Glennon RA, Negus SS.

Eur Neuropsychopharmacol. 2016 Feb;26(2):288-297. doi: 10.1016/j.euroneuro.2015.12.010. Epub 2015 Dec 11.

48.

Abuse-Related Neurochemical Effects of Para-Substituted Methcathinone Analogs in Rats: Microdialysis Studies of Nucleus Accumbens Dopamine and Serotonin.

Suyama JA, Sakloth F, Kolanos R, Glennon RA, Lazenka MF, Negus SS, Banks ML.

J Pharmacol Exp Ther. 2016 Jan;356(1):182-90. doi: 10.1124/jpet.115.229559. Epub 2015 Oct 15.

49.

Expression and pharmacological modulation of visceral pain-induced conditioned place aversion in mice.

Bagdas D, Muldoon PP, AlSharari S, Carroll FI, Negus SS, Damaj MI.

Neuropharmacology. 2016 Mar;102:236-43. doi: 10.1016/j.neuropharm.2015.11.024. Epub 2015 Nov 27.

Supplemental Content

Loading ...
Support Center